THERMO FISHER SCIENTIFIC Annual Meeting of Shareholders 2024
Marc N. Casper
Chairman, President and Chief Executive Officer
Julia L. Chen
Vice President and Corporate Secretary
The world leader in serving science
Proprietary | May 22, 2024
Annual Meeting of Shareholders
Meeting Agenda
- Call to Order and Instructions
- Voting Items
- Questions and Answers on Voting Matters
- Closing of Polls
- Preliminary Voting Report
- Management Presentation
- Questions and Answers
- Adjournment
2 Proprietary | May 22, 2024
Annual Meeting of Shareholders
Safe Harbor Statement
Various remarks that we may make about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Company's most recent Annual Report on Form 10-K under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our website under the heading "SEC Filings." While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Non-GAAP Measures
During this presentation, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. The non-GAAP financial measures of Thermo Fisher's results of operations and cash flows included in this presentation are not meant to be considered superior to or a substitute for Thermo Fisher's results of operations prepared in accordance with GAAP. Definitions of these non-GAAP financial measures, as well as, for historical periods, a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures, are available as an
appendix to this presentation, which can be found under "News & Events" in the "Investors" section of our website,
thermofisher.com.
3 Proprietary | May 22, 2024
Annual Meeting of Shareholders
Voting Matters
- Proposal 1: Election of Directors
- Proposal 2: Approval of an Advisory Vote on Executive Compensation
- Proposal 3: Ratification of the Selection of the Independent Auditors for 2024
- Proposal 4: Shareholder Proposal to Adopt a Simple Majority Vote
4 Proprietary | May 22, 2024
Questions
Annual Meeting of Shareholders 2024
5 Proprietary | May 22, 2024
Annual Meeting of Shareholders
Voting Matters
- Proposal 1: Election of Directors
- Proposal 2: Approval of an Advisory Vote on Executive Compensation
- Proposal 3: Ratification of the Selection of the Independent Auditors for 2024
- Proposal 4: Shareholder Proposal to Adopt a Simple Majority Vote
6 Proprietary | May 22, 2024
Company Overview Annual Meeting of Shareholders 2024
Marc N. Casper
Chairman, President and Chief Executive Officer
The world leader in serving science
Proprietary | May 22, 2024
The world leader in serving science
$43B | >120,000 | $1.3B | ||
revenue | colleagues | R&D investment | ||
Industry-leading scale | Unmatched depth of capabilities | Sustainable value creation | |||||
• | Exceptional commercial reach | • | Leading innovative | • | Comprehensive biopharma | • | Positive societal impact |
• | Unique customer access | • | technologies | • | services offering | • | Comprehensive ESG strategy |
• | Extensive global footprint | Deep applications | Premier productivity partner | ||||
expertise | |||||||
Powered by our Practical Process Improvement (PPI) Business System
8 NOTE: Amounts based on Q1 2024 TTM
Our Mission is our purpose
We enable our customers to make the world healthier, cleaner and safer
9
Very attractive revenue profile
Leadership in fast-growing end markets
Enabling advanced materials to power the digital economy and the clean
Very strong | Unparalleled | |
recurring revenue mix | commercial engine | |
energy transition
Industrial
& Applied
Enabling | 13% | ||
Precision | Diagnostics | ||
Medicine | & Healthcare | End | Pharma |
15% | & Biotech | ||
markets | 57% | ||
Academic &
Government
15%
Powering the
Golden Age of
Biology
10 NOTE: Revenue and percentages based on unaudited TTM through Q1 2024
Instruments
17%
Products
Services & consumables
83%
Revenue: $42.5B
ROW
4%
Asia-Pacific
18%
North
Regions America
53%
Europe
25%
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Thermo Fisher Scientific Inc. published this content on 22 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 May 2024 13:14:07 UTC.
